1. Home
  2. TIC vs AUPH Comparison

TIC vs AUPH Comparison

Compare TIC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TIC

Acuren Corporation

N/A

Current Price

$8.45

Market Cap

1.9B

Sector

N/A

ML Signal

N/A

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

N/A

Current Price

$14.80

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TIC
AUPH
Founded
1991
1993
Country
United States
Canada
Employees
6060
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
TIC
AUPH
Price
$8.45
$14.80
Analyst Decision
Buy
Buy
Analyst Count
4
4
Target Price
$14.63
$17.25
AVG Volume (30 Days)
1.9M
883.5K
Earning Date
01-01-0001
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5075.00
EPS
N/A
2.07
Revenue
N/A
$283,055,000.00
Revenue This Year
$42.16
$17.35
Revenue Next Year
$43.21
$15.66
P/E Ratio
N/A
$7.14
Revenue Growth
N/A
20.38
52 Week Low
$8.42
$6.83
52 Week High
$14.94
$16.54

Technical Indicators

Market Signals
Indicator
TIC
AUPH
Relative Strength Index (RSI) 34.76 54.14
Support Level N/A $14.56
Resistance Level $11.51 $15.23
Average True Range (ATR) 0.44 0.56
MACD -0.08 0.06
Stochastic Oscillator 14.25 74.42

Price Performance

Historical Comparison
TIC
AUPH

About TIC Acuren Corporation

TIC Solutions Inc is a provider of tech-enabled Testing, Inspection, Certification and Compliance (TICC), engineering, and geospatial services. It provides mission-critical services that are essential to the safety, reliability, and efficiency of industrial assets, buildings and public infrastructure. The company's services are often non-discretionary and are driven by regulatory requirements, customer risk management policies, and the need to extend the useful life of critical assets. It operates in North America and serve both public- and private-sector clients. Its public-sector clients include federal, state, and municipal agencies, public utilities, and environmental regulators. Its private-sector clients span industrial, infrastructure, construction, and real estate end markets.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: